利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.027 秒)

    Humanized monoclonal antibody HPAM4
    2.
    发明公开
    Humanized monoclonal antibody HPAM4 审中-公开
    Humanisierter单克隆抗体AntikörperHPAM4

    公开(公告)号：EP2301968A2

    公开(公告)日：2011-03-30

    申请号：EP10012295.1

    申请日：2003-06-16

    申请人： Immunomedics, Inc.

    发明人： Goldenberg, David M. ,  Hansen, Hans ,  Qu, Zhengxing

    IPC分类号： C07K16/18 ,  A61K39/395 ,  G01N33/15 ,  C12N15/13 ,  C12N5/20 ,  A61K47/48 ,  A61K51/10 ,  G01N33/68 ,  C07K16/46

    CPC分类号： A61K49/0008 ,  A61K47/68 ,  A61K51/1057 ,  A61K2039/505 ,  C07K14/4748 ,  C07K16/2896 ,  C07K2317/24

    摘要： This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to humanized and human PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.

    摘要翻译： 本发明涉及单价和多价单特异性抗体和多价多特异性抗体。 这些抗体的一个实施方案具有一个或多个相同的结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些抗体的另一个实施方案具有两个或多个结合位点，其中这些结合位点对靶抗原或不同靶抗原上的不同表位具有亲和力，或对靶抗原和半抗原具有亲和性。 本发明还涉及可用于在宿主中表达这些功能性抗体的重组载体。 更具体地，本发明涉及称为PAM4的肿瘤相关抗体。 本发明还涉及人源化和人类PAM4抗体，以及这些抗体在诊断和治疗中的用途。

    Vaccines against cancer and infectious diseases
    5.
    发明公开
    Vaccines against cancer and infectious diseases 失效
    Impfstoffe gegen Krebs und Infektionskrankheiten。

    公开(公告)号：EP0438803A2

    公开(公告)日：1991-07-31

    申请号：EP90125701.4

    申请日：1990-12-28

    申请人： IMMUNOMEDICS, INC.

    发明人： Goldenberg, David M. ,  Hansen, Hans J.

    IPC分类号： A61K39/395 ,  A61K39/39

    CPC分类号： A61K39/39566 ,  Y02A50/403 ,  A61K2300/00

    摘要： A method of stimulating an immune response in a human against malignant cells or an infectious agent comprises the step of administering to the human an immunogenic amount of a primate anti-idiotype antibody or antibody fragment that acts as an immunogenic functional mimic of an antigen produced by or associated with a malignant cell or an infectious agent. Sub-human primate anti-idiotype antisera, especially from baboons, are preferred. Such anti-idiotype antibodies are used to make vaccines for inducing preventive immunity or a therapeutic immune response against tumors, viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and multicellular parasites.

    摘要翻译： 刺激人体对恶性细胞或感染性物质的免疫反应的方法包括向人体施用免疫原性量的灵长类抗独特型抗体或抗体片段的步骤，该抗体或抗体片段作为由以下产生的抗原的免疫原性功能模拟物： 或与恶性细胞或感染因子相关联。 亚人灵长类抗独特型抗血清，特别是狒狒是优选的。 这种抗独特型抗体用于制备用于诱导针对肿瘤，病毒，细菌，立克次体，支原体，原生动物，真菌和多细胞寄生虫的预防性免疫或治疗性免疫应答的疫苗。

    Immunotherapy of B-cell malignancies using anti-CD22 antibodies
    10.
    发明公开
    Immunotherapy of B-cell malignancies using anti-CD22 antibodies 失效
    通过抗CD22抗体恶性B细胞的免疫疗法

    公开(公告)号：EP1459768A3

    公开(公告)日：2008-10-15

    申请号：EP04075774.2

    申请日：1998-03-17

    申请人： Immunomedics, Inc.

    发明人： Goldenberg, David M.

    IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K31/00 ,  A61K38/19

    CPC分类号： C07K16/2803 ,  A61K38/00 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2300/00

    摘要： B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.